Physician profile
John Christopher Moore
NPI 1790852895
$1,666.23
in general payments reported to CMS, 2019-2025
26 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $44.66 · 2021: $71.66 · 2022: $384 · 2023: $505 · 2024: $234 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $528.44 | 2019-2025 | Stravix, Grafix Pl, Stravix Pl |
| Acera Surgical, INC. | $212.74 | 2022-2023 | Restrata Wound Matrix |
| Averitas Pharma INC. | $161.48 | 2023-2025 | Qutenza |
| Nevro Corp. | $110.35 | 2022-2024 | Senza |
| Amniox Medical, INC. | $99.99 | 2019 | |
| Next Science LLC | $97.37 | 2022-2023 | Surgx, Blastx, Xperience |
| Stryker Corporation | $67.80 | 2019-2024 | Variax, Spy-Phi System, Actishield Cf |
| Organogenesis INC. | $44.23 | 2021-2024 | |
| Medtronic, INC. | $43.13 | 2024 | Intellis Adaptivestim |
| Kerecis Limited | $24.40 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ibsa Pharma INC. | $22.08 | 2023 | Tirosint, Licart |
| Musculoskeletal Transplant Foundation INC. | $21.76 | 2022 | |
| Ovik Health, LLC | $21.12 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.05 | 2025 | |
| Access Pro Medical, LLC | $20.79 | 2023 | Matriderm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $19.53 | 2019 | |
| Paragon 28, INC. | $19.17 | 2019 | |
| Reapplix INC. | $18.64 | 2025 | 3c Patch Kit - Box |
| Sanara Medtech INC. | $18.18 | 2025 | Celleraterx |
| Bioventus LLC | $17.72 | 2019 | |
| Horizon Therapeutics Plc | $16.48 | 2021 | |
| Solventum Corporation | $16.32 | 2024 | Activ.A.C. |
| Kci USA, INC. | $15.96 | 2019 | |
| Zimmer Biomet Holdings, INC. | $14.39 | 2021 | |
| Melinta Therapeutics, LLC | $13.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$87,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.